Type II RAF inhibitor tovorafenib for the treatment of pediatric low-grade glioma
Sign Up to like & getrecommendations! Published in 2024 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2024.2418405
Abstract: ABSTRACT Introduction Pediatric low-grade glioma (pLGG) is the most prevalent childhood brain tumor group, currently regarded as a chronic disease. On 23 April 2024, the U.S. FDA approved a new type II RAF inhibitor, tovorafenib… read more here.
Keywords: pediatric low; plgg; treatment; grade glioma ... See more keywords
LGG-18. BEVACIZUMAB: GOOD FOR EYES AND MRI’S! A NATIONAL UK ASSESSMENT OF VISUAL AND RADIOLOGICAL OUTCOMES OF BEVACIZUMAB THERAPY IN PAEDIATRIC LOW-GRADE GLIOMA (PLGG)
Sign Up to like & getrecommendations! Published in 2024 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noae064.411
Abstract: Abstract INTRODUCTION Bevacizumab (BEV) is increasingly used for PLGGs in varying manners despite limited evidence. The potential for BEV to preserve or rescue vision in OPGs has not yet been explored. We performed a nationwide… read more here.
Keywords: visual radiological; plgg; treatment; response ... See more keywords
P10.18.A THE IMPACT OF PUBERTAL STATE ON THE ONSET AND PROGRESSION OF PEDIATRIC LOW-GRADE GLIOMAS: CAUSAL ASSOCIATION OR UNDERLYING BIOLOGICAL MECHANISM?
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf193.329
Abstract: Pediatric low-grade gliomas (pLGG) are the most common central nervous system tumors in children, with an incidence of 10-12 cases per million annually. Estrogen receptors (ER-α, ER-β, and GPER) are expressed in pLGG and have… read more here.
Keywords: plgg; progression; precocious puberty; tumor ... See more keywords